12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CP024: Phase I data

Critical Pharmaceuticals reported data from a Phase I trial in 7 healthy volunteers showing that 2-6 mg doses of intranasal CP024 plus an infusion of...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >